Details for New Drug Application (NDA): 212895
✉ Email this page to a colleague
NDA 212895 describes CONJUPRI, which is a drug marketed by Cspc Ouyi and is included in one NDA. It is available from one supplier. Additional details are available on the CONJUPRI profile page.
The generic ingredient in CONJUPRI is levamlodipine maleate. One supplier is listed for this compound. Additional details are available on the levamlodipine maleate profile page.
The generic ingredient in CONJUPRI is levamlodipine maleate. One supplier is listed for this compound. Additional details are available on the levamlodipine maleate profile page.
Summary for 212895
| Tradename: | CONJUPRI |
| Applicant: | Cspc Ouyi |
| Ingredient: | levamlodipine maleate |
| Patents: | 0 |
Suppliers and Packaging for NDA: 212895
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| CONJUPRI | levamlodipine maleate | TABLET;ORAL | 212895 | NDA | CSPC Ouyi Pharmaceutical Co. Ltd | 24075-0411 | 24075-0411-3 | 2.5 mg in 1 BOTTLE (24075-0411-3) |
| CONJUPRI | levamlodipine maleate | TABLET;ORAL | 212895 | NDA | CSPC Ouyi Pharmaceutical Co. Ltd | 24075-0411 | 24075-0411-5 | 2.5 mg in 1 BOTTLE (24075-0411-5) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | EQ 1.25MG BASE | ||||
| Approval Date: | Dec 19, 2019 | TE: | RLD: | Yes | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | EQ 2.5MG BASE | ||||
| Approval Date: | Dec 19, 2019 | TE: | RLD: | Yes | |||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | EQ 5MG BASE | ||||
| Approval Date: | Dec 19, 2019 | TE: | RLD: | Yes | |||||
Complete Access Available with Subscription
